Ratio Therapeutics Inc.

About Ratio Therapeutics Inc.

Ratio Therapeutics is a discovery through early clinical phase pharmaceutical company focused on developing best-in-class targeted radiotherapeutics for the treatment of cancers using innovative technologies.

Products & Services

Trillium™ Targeting Scaffold:A proprietary small molecule targeting agent that combines pharmacokinetic modulation with advanced chelation technology to attack a broad array of cancer targets.

Theranostics Platform:A de-risked platform accommodating imaging and therapeutic radioisotopes, with tunable properties and small-scale imaging trials for accelerated compound selection.

Specialties

Radiopharmaceuticals Cancer Treatment Theranostics Pharmacokinetic Modulation Chelation Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 50000000 MR: - FA: $50M FAN: 50000000	D: 2024-01-17 FD: 2024-01-17	5 investors
2	RT: Series A T: - FT: Series A	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2023-02-01 FD: 2023-02-01	3 investors

Series B Latest

2024-01-17

$50.0M

5 investors (Pro only)

Series A 2023-02-01

$20.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jack Hoppin, Ph.D.

Chairman, Chief Executive Officer

J

John Babich, Ph.D.

Director, President, Chief Scientific Officer

M

Marc Becker, M.B.A, CPA

Chief Financial and Operating Officer

W

William Cupelo, M.B.A, M.S.

Chief Business Officer

M

Matthias Friebe, Ph.D.

Chief Technology Officer

S

Scott Holbrook

Chief Commercial and Manufacturing Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News